Longitudinal association between sUA and the incidence of any fatal or nonfatal CVD endpoints by year 27.

<p>sUA, serum urate; CVD, cardiovascular disease; Y, year; Q, quartile; BMI, body mass index; CI, confidence interval.</p><p>^a Model 1: adjusted for year 0 age, sex, race, clinic, education level, smoking status, physical activity and intakes of total calories, alcohol and protein.</p><p>^b Model 1 + year 0 BMI, systolic and diastolic blood pressure, anti-hypertension medication use (excluding those taking diuretics), diuretics use, and glomerular filtration rate.</p><p>^c Model 2: adjusted for age, sex, race, clinic, education level, smoking status and physical activity at year 10, and average intakes of total calories, alcohol and protein at years 0 and 7.</p><p>^d Model 2 + year 10 BMI, systolic and diastolic blood pressure, anti-hypertension medication use (excluding those taking diuretics), diuretics use, and glomerular filtration rate.</p><p>^e Model 3: adjusted for age, sex, race, clinic, education level, smoking status and physical activity at year 15, and average intakes of total calories, alcohol and protein at years 0 and 7.</p><p>^f Model 3 + year 15 BMI, systolic and diastolic blood pressure, anti-hypertension medication use (excluding those taking diuretics), diuretics use, and glomerular filtration rate</p><p>^g Hazard ratio (95% CI) for the incidence of any fatal or nonfatal CVD endpoints by the end of 2012 (year 25) across sUA tertiles, reference group is participants in the lowest tertile of sUA concentrations.</p><p>^h Hazard ratio (95% CI) for the incidence of any fatal or nonfatal CVD endpoints per mg/dL sUA when using continuous sUA variable.</p><p>ⁱ<i>P</i>-values for the association between sUA and CVD when using continuous sUA variables.</p><p>^j Values are presented as “hyperuricemia group (reference group)”. Numbers in the reference group (participants without hyperuricaemia, i.e. sUA <6.8 mg/dL) are given in parentheses.</p><p>^kHazard ratio (95% CI) for the incidence of any fatal or nonfatal CVD endpoints by the end of 2012 (year 25) for the hyperuricemia group.</p><p>Longitudinal association between sUA and the incidence of any fatal or nonfatal CVD endpoints by year 27.